Zefylti

Zefylti (Filgrastim) is a biologic used to stimulate white blood cell production in patients undergoing chemotherapy. This injectable medication supports immune function during treatment. Suitable for intravenous or subcutaneous use. Always consult a healthcare provider before use.

Zefylti is primarily used to reduce the risk of infection in patients receiving chemotherapy by increasing white blood cell counts. It may also be prescribed for stem cell transplant patients to help the body produce new blood cells. The medication works by mimicking a natural protein in the body that supports immune function. It is not indicated for all types of infections or conditions.

Patients using Zefylti may experience mild to moderate effects such as bone pain, headache, or redness at the injection site. Some individuals report flu-like symptoms shortly after administration. These effects are generally temporary and vary by person. Proper hydration and rest can help manage discomfort.

Zefylti should be handled with care to avoid contamination or infection. Patients with a history of allergic reactions to biologics should use caution. Regular blood monitoring is recommended during treatment to assess white blood cell levels. Keep the medication refrigerated and protect it from light until use.

Zefylti may interact with other medications that affect bone marrow function, such as chemotherapy drugs. Combining it with lithium could enhance its effects, potentially increasing white blood cell counts further. Always inform your healthcare provider about all medications and supplements you are taking before starting Zefylti.